Table 3.
Variable tested | CRP (mg/l) | CEA (ng/ml) | SCC‐Ag (ng/ml) | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Median | Range | P‐value | Median | Range | P | Median | Range | P‐value | ||
Group tested | AC (n = 23) | 6.2A | 5.0–45.5 | <0.001* | 2.5A | 0.4–40.4 | <0.001* | 0.9 | 0.4–4.5 | 0.301 |
Control group (n = 90) | 5.0 | 0.1–13.9 | 0.8 | 0.1–11.4 | 1.0 | 0.6–4.0 | ||||
TNM stage | I + IIa + IIb (n = 3) | 5.0 | 5.0–45.5 | 0.995 | 1.9 | 0.5–2.6 | 0.257 | 1.0 | 0.9–1.4 | 0.600 |
III (n = 16) | 7.8A | 5.0–41.8 | 4.0A | 0.4–40.4 | 0.9 | 0.4–4.5 | ||||
IV (n = 4) | 10.3 | 5.0–40.5 | 1.2 | 0.4–7.8 | 0.9 | 0.5–1.0 | ||||
Depth of tumor invasion (T factor) | T1 + T2 (n = 3) | 5.0 | 5.0–45.5 | 0.357 | 1.9 | 0.5–2.6 | 0.676 | 1.0 | 0.9–1.4 | 0.038* |
T3 (n = 15) | 5.0A | 5.0–45.5 | 2.5A | 0.8–40.4 | 0.9 | 0.4–4.5 | ||||
T4 (n = 15) | 20.9 | 5.0–41.8 | 7.5 | 0.4–23.8 | 0.7** | 0.5–0.9 | ||||
Nodal involvement (N factor) | N0 (n = 3) | 5.0 | 5.0–45.5 | 0.923 | 1.9 | 0.5–2.6 | 0.411 | 1.0 | 0.9–1.4 | 0.463 |
N1 (n = 20) | 7.8A | 5.0–41.8 | 2.6A | 0.4–40.4 | 0.9 | 0.4–4.5 | ||||
Distant metastases (M factor) | M0 (n = 19) | 6.2A | 5.0–45.5 | 0.966 | 2.6A | 0.4–40.4 | 0.208 | 0.9 | 0.4–4.5 | 0.415 |
M1 (n = 4) | 10.3 | 5.0–40.5 | 1.2 | 0.4–7.8 | 0.9 | 0.5–1.0 | ||||
Differentiation of tumor | G1 (n = 4) | 7.2 | 5.0–15.5 | 0.222 | 2.2A | 0.9–7.8 | 0.781 | 1.2 | 1.0–4.5 | 0.090 |
G2 (n = 12) | 5.0A | 5.0–45.5 | 2.7A | 0.5–40.4 | 0.9 | 0.4–2.2 | ||||
G3 (n = 7) | 23.0A | 5.0–41.8 | 1.6 | 0.4–23.8 | 0.7A | 0.5–1.4 | ||||
Survival of patients | Alive (n = 15) | 5.0A | 5.0–41.8 | 0.259 | 2.6A | 0.4–40.4 | 0.301 | 1.0 | 0.4–2.2 | 0.364 |
Died of cancer (n = 8) | 18.2A | 5.0–45.5 | 1.2 | 0.4–23.8 | 0.9 | 0.5–4.5 |
*Statistically significant when P < 0.05.
**Statistically significant in comparison with stage III post hoc Dwass‐Steel‐Critchlow‐Fligner test, P = 0.047.
Statistically significant in comparison with control group.